Cooperative Agreement U01CA294062
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$559K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Boston, MA 02115, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $601,250 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to St. Jude Children's Research Hospital Inc. This award supports research to understand the mechanisms underlying oncogenesis driven by the ZFTA-RELA gene fusion, known as ZRFUS, in the aggressive pediatric brain tumor ependymoma. The research aims to elucidate how ZRFUS forms chromatin-associated condensates to regulate oncogenic gene expression...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research into the mechanisms underlying breast cancer development in BRCA1 mutation carriers. The total award of $527,159 will fund a 5-year project at Brigham & Women's Hospital Inc., a prominent academic medical center in Boston, Massachusetts. The key research objectives are to: 1) Determine if BRCA1-deficient luminal mammary epithelial cells acquire a fetal mammary stem...
The National Cancer Institute (NCI) awarded a $170,640 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant will fund research to investigate the role of the histone demethylase KDM4C in driving tumor growth in triple-negative breast cancer. The project aims to determine if KDM4C prevents the proteolytic cleavage of the N-terminal tail of histone H3 by the enzyme cathepsin L, and whether this...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,203,647.00 in funding to The University of Texas Southwestern Medical Center to advance small molecule drug discovery targeting transcriptional fusion oncoproteins. The goal is to identify and develop small molecules that impair the function of these fusion proteins, which drive oncogenic gene expression programs in cancers like Ewing sarcoma and rhabdomyosarcoma. The key...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $738,024 to St. Jude Children's Research Hospital to develop high-quality chemical probes to study the chromatin binding domains of the epigenetic regulator BPTF in neuroblastoma. The goal is to elucidate the roles of the BPTF bromodomain (BRD) and plant homeodomain (PHD) in regulating oncogenic gene expression networks, particularly those involving MYC and MYCN, with the aim of...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will provide $720,252 to the Dana-Farber Cancer Institute (DFCI) from April 1, 2025 to March 31, 2030 to characterize the genetic risk of cancer across diverse populations. The key products and services to be delivered include: Identifying chromatin quantitative trait loci (cQTLs) that confer risk of prostate cancer in men of African ancestry by...
The National Cancer Institute (NCI) awarded a $718,113 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to St. Jude Children's Research Hospital Inc. to study the role of epigenetic modifiers in promoting neuroblastoma malignancy and plasticity. The research aims to determine how the BHLH transcription factor TCF4 interacts with histone deacetylases (HDACs) to enforce pro-oncogenic core regulatory circuitry transcription factors (CRC TFs) driven by MYC oncogenes...
This $660,205 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to identify small molecule inhibitors targeting the bromodomain-containing protein 4 (BRD4) to block human papillomavirus (HPV) genome replication. The award aims to: 1) Identify compounds that effectively inhibit HPV replication, and 2) Define the mechanistic action of phospho-BRD4-targeting compounds. This work will involve...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $678,879 in funding to Cold Spring Harbor Laboratory to conduct research on re-establishing tumor suppression in glioblastoma, the most common and deadly adult brain cancer. The 5-year project aims to elucidate the epigenetic mechanism by which targeting the chromatin regulator BRD8 can reactivate the p53 tumor suppressor pathway in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) in the amount of $431,968 is supporting research to elucidate how the oncogene MYCN rewires the metabolic environment of neuroblastoma tumors to drive immune suppression. The research aims to modulate the metabolic environment of MYCN-driven neuroblastoma tumors to enhance immune-based treatment approaches for this high-risk cancer. The research is being conducted by the prime...